Asymmetric synthesis of the C1-C16 segment of lasonolide A

European Journal of Organic Chemistry

Volumn , Issue 11, 1999, Pages 2991-2995

  Beck, Hartmut ^a,b   Hoffmann, H Martin R ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b BAYER AG   (Germany)

Author keywords

Macrocyclic factone; Marine natural products; Polyketide; Stereoselective carbonyl olefination

Indexed keywords

ANTINEOPLASTIC AGENT; LASONOLIDE A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LUNG CARCINOMA; STEREOCHEMISTRY;

EID: 0032742949     PISSN: 1434193X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-0690(199911)1999:11<2991::aid-ejoc2991>3.3.co;2-q     Document Type: Article

References (24)

1. P. A. Horton, F. E. Koehn, R. E. Longley, O. J. McConnell, J. Am. Chem. Soc. 1994, 116, 6015-6016.
2. M. Nowakowski, H. M. R. Hoffmann, Tetrahedron Lett. 1997, 38, 1001. See also: M. K. Gurjar, A. Chakrabarti, B. V. Rao, P. Kumar, Tetrahedron Lett. 1997, 38, 6885; M. K. Gurjar, P. Kumar, B. V. Rao, Tetrahedron Lett. 1996, 37, 8617.
3. M. Nowakowski, H. M. R. Hoffmann, Tetrahedron Lett. 1997, 38, 1001. See also: M. K. Gurjar, A. Chakrabarti, B. V. Rao, P. Kumar, Tetrahedron Lett. 1997, 38, 6885; M. K. Gurjar, P. Kumar, B. V. Rao, Tetrahedron Lett. 1996, 37, 8617.
4. M. Nowakowski, H. M. R. Hoffmann, Tetrahedron Lett. 1997, 38, 1001. See also: M. K. Gurjar, A. Chakrabarti, B. V. Rao, P. Kumar, Tetrahedron Lett. 1997, 38, 6885; M. K. Gurjar, P. Kumar, B. V. Rao, Tetrahedron Lett. 1996, 37, 8617.
5. [3a] Spongistatin C29-C37 segment: R. Dunkel, J. Treu, H. M. R. Hoffmann, Tetrahedron: Asymmetry 1999, 10, 1539.
6. [3b] Discodermolide C1-C7 segment and Phorboxazole C20-C26 segment: A. Misske, H. M. R. Hoffmann, Tetrahedron 1999, 55, 4315.
7. [3c] Phorboxazole C3-C13 segment: P. Wolbers, H. M. R. Hoffmann, Tetrahedron 1999, 55, 1905.
8. [3d] Phorboxazole C28-C41 segment: P. Wolbers, H. M. R. Hoffmann, Synthesis 1999, 797.
9. [3e] Mevinic Acids tetrahydropyran unit: R. Dunkel, M. Mentzel, H. M. R. Hoffmann, Tetrahedron 1997, 53, 14929.
10. [3f] Bryostatin C1-C9 segment: J. Weiss, H. M. R. Hoffmann, Tetrahedron: Asymmetry 1997, 8, 3913.
11. [2]
12. [3h] Bryostatin: T. F. J. Lampe, H. M. R. Hoffmann, J. Chem. Soc., Chem. Commun. 1996, 1931.
13. [3a]
14. [3b]
15. J. Treu, H. M. R. Hoffmann, J. Org. Chem. 1997, 62, 4650.
16. H. C. Brown, N. N. Joshi, J. Org. Chem. 1988, 53, 4059
17. A "racemic switch" has been defined as "the redevelopment in single-enantiomer form of a drug that was first approved as a racemate"; see: S. C. Stinson, Chem. Eng. News 1998, September 21, 83-104. In our case the early racemic switch provides two key single-isomer precursors of structurally different bioactive natural products.
18. [8a] P. Schäfer, unpublished work.
19. [8b] The ozonolysis was performed following a lead by: P. Schäfer, PhD thesis, in preparation.
20. [9a] K. Gerth, D. Schummer, G. Höfle, H. Irschik, H. Reichenbach, J. Antibiotics 1995, 48, 973.
21. [9b] D. Schummer, K. Gerth, H. Reichenbach, G. Höfle, Liebigs Ann. 1995, 685.
22. [10a] The olefinatjon procedure is described in: W. C. Still, C. Gennari, Tetrahedron Lett. 1983, 24, 4405.
23. 2Et was prepared according to the procedure recorded in: C. Patois, P. Savignac, Synth. Commun. 1991, 21, 2391.
24. The yield is 12% with respect to the early racemic switch rac-1.